7. Asp N, Pust S, Sandvig K. Flotillin depletion affects ErbB protein levels in different human breast cancer cells. Biochim Biophys Acta, 2014, 1843(9):1987-1996.
[2]
8. Jullien N, Dieudonné FX, Habel N, et al. ErbB3 silencing reduces osteosarcoma cell proliferation and tumor growth in vivo. Gene, 2013, 521(1):55-61.
[3]
9. Cao CM, Yang FX, Wang PL, et al. Clinicopathologic significance of S100A4 expression in osteosarcoma. Eur Rev Med Pharmacol Sci, 2014, 18(6):833-839.
[4]
18. Citri A, Yarden Y. EGF-ERBB signaling:towards the systems level. Nat Rev Mol Cell Biol, 2006, 7(7):505-516.
[5]
19. Cook RS, Garrett JT, Sanchez V, et al. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res, 2011, 71(11):3941-3951.
[6]
20. Amaddii M, Meister M, Banning A, et al. Flotillin-1/reggie-2 protein plays dual role in activation of receptor-tyrosine kinase/mitogen-activated protein kinase signaling. J Biol Chem, 2012, 287(10):7265-7278.
[7]
21. Solis GP, Schrock Y, Hülsbusch N, et al. Reggies/flotillins regulate E-cadherin-mediated cell contact formation by affecting EGFR trafficking. Mol Biol Cell, 2012, 23(10):1812-1825.
[8]
22. Zhu Z, Wang J, Sun Z, et al. Flotillin2 expression correlates with HER2 levels and poor prognosis in gastric cancer. PLoS One, 2013, 8(5):e62365.
[9]
10. Tanner B, Hasenclever D, Stern K, et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol, 2006, 24(26):4317-4323.
[10]
11. Tang N, Song WX, Luo J, et al. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res, 2008, 466(9):2114-2130.
[11]
12. Himelstein BP. Osteosarcoma and other bone cancers. Curr Opin Oncol, 1998, 10(4):326-333.
[12]
13. Jaffe N. Osteosarcoma:review of the past, impact on the future. The American experience. Cancer Treat Res, 2009, 152:239-262.
[13]
1. Baselga J, Swain SM. Novel anticancer targets:revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer, 2009, 9(7):463-475.
[14]
2. Holbro T, Beerli RR, Maurer F, et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit:ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A, 2003, 100(15):8933-8938.
[15]
3. Pust S, Klokk TI, Musa N, et al. Flotillins as regulators of ErbB2 levels in breast cancer. Oncogene, 2013, 32(29):3443-3451.
[16]
4. Neumann-Giesen C, Falkenbach B, Beicht P, et al. Membrane and raft association of reggie-1/flotillin-2:role of myristoylation, palmitoylation and oligomerization and induction of filopodia by overexpression. Biochem J, 2004, 378(Pt 2):509-518.
[17]
5. Kato N, Nakanishi M, Hirashima N. Flotillin-1 regulates IgE receptor-mediated signaling in rat basophilic leukemia (RBL-2H3) cells. J Immunol, 2006, 177(1):147-154.
[18]
6. Berger T, Ueda T, Arpaia E, et al. Flotillin-2 deficiency leads to reduced lung metastases in a mouse breast cancer model. Oncogene, 2013, 32(41):4989-4994.
[19]
14. Sithanandam G, Fornwald LW, Fields J, et al. Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene, 2005, 24(11):1847-1859.
[20]
15. Soler M, Mancini F, Meca-Cortes O, et al. HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. Int J Cancer, 2009, 125(11):2565-2575.
[21]
16. Chen N, Ye XC, Chu K, et al. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res, 2007, 67(14):6544-6548.
[22]
17. Vakar-Lopez F, Cheng CJ, Kim J, et al. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol, 2004, 203(2):688-695.
[23]
23. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2001, 2(2):127-137.
[24]
24. Yarden Y, Pines G. The ERBB network:at last, cancer therapy meets systems biology. Nat Rev Cancer, 2012, 12(8):553-563.
